Amendments to the Claims/Listing of Claims

Please amend claims 1, 16, 58, 128 and 145 as follows. This listing of claims will replace all prior versions, and listings of claims in the application:

1. (Currently amended) A unit dosage form comprising a sealed vial containing a ~~sufficient~~ quantity of cremophor-free **nanoparticles of** taxane**, associated with a biocompatible polymer, sufficient** to provide for administration to a human subject a total dose of taxane in the range of about 30 mg/m^2 to about 1000 mg/m^2 over an administration period no greater than about 3 hours, wherein the cycle time between administrations of said total dose is less than about three weeks.

2. (Previously presented) A unit dosage form according to claim 1, wherein said total dose is in the range of about 50 mg/m^2 to about 700 mg/m^2.

3. (Previously presented) A unit dosage form according to claim 1, wherein said total dose is in the range of about 175 mg/m^2 to about 300 mg/m^2.

4-11. (Canceled)

12. (Original) A unit dosage form according to claim 1, wherein said taxane is administered locally.

13. (Original) A unit dosage form according to claim 1, wherein said taxane is administered systemically.

14. (Original) A unit dosage form according to claim 1, wherein said taxane is in a non-aqueous formulation.

15. (Previously presented) A unit dosage form according to claim 1, wherein said taxane is docetaxel.

16. (Currently amended) A unit dosage form according to claim 1, wherein said taxane **is** a paclitaxel analog.

17-57. (Canceled)

58. (Currently amended) A unit dosage form comprising a sealed vial containing a ~~sufficient~~ quantity of cremophor-free **nanoparticles of** taxane**, associated with a biocompatible polymer, sufficient** to provide for administration to a human subject a total dose of taxane in the range of about 4 mg to about 822 mg over an administration period of no greater than 3 weeks, wherein the cycle time between administrations of said total dose is less than about three weeks.

59. (Previously presented) A unit dosage form according to claim 58, wherein said total dose comprises in the range of about 30 mg to about 700 mg of said taxane.

60. (Previously presented) A unit dosage form according to claim 58, wherein said total dose comprises in the range of about 100 mg to about 400 mg of said taxane.

61-73. (Canceled).

74. (Original) A unit dosage form according to claim 58, wherein said taxane is administered locally.

75. (Original) A unit dosage form according to claim 58, wherein said taxane is administered systemically.

76. (Original) A unit dosage form according to claim 58, wherein said taxane is in a non-aqueous formulation.

77. (Previously presented) A unit dosage form according to claim 58, wherein said taxane is docetaxel.

78. (Original) A unit dosage form according to claim 58, wherein said taxane is a paclitaxel analog.

79-127. (Canceled).

128. (Currently amended) A cremophor-free taxane containing formulation contained within a sealed vial suitable for the delivery to a human subject of a total dose of **cremophor-free nanoparticles of** taxane, **associated with a biocompatible polymer,** in the range of about 30 mg/m^2 to about 1000 mg/m^2, with an administration period of no greater than about 3 hours, wherein the cycle time between administrations of said total dose is less than about three weeks.

129. (Original) A formulation according to claim 128, wherein said total dose of taxane is in the range of about 80 mg/m^2 to about 700 mg/m^2.

130. (Previously presented) A formulation according to claim 128, wherein said taxane is docetaxel.

131. (Original) A formulation according to claim 128, wherein said taxane is a paclitaxel analog.

132-144. (Canceled).

145. (Currently amended) A method for administration of ~~cremophor-free~~ taxane to a human subject in need thereof, said method comprising administering in the range of about 30 mg/m^2 to about 1000 mg/m^2 of ~~said~~ **cremophor-free nanoparticles of** taxane**, associated with a biocompatible polymer,** to said subject in a pharmaceutically acceptable formulation contained within a sealed vial with a treatment cycle no greater than about 3 weeks, wherein said administration period is no greater than about 3 hours.

146. (Previously presented) A method according to claim 145, wherein said taxane is docetaxel.

147. (Original) A method according to claim 145, wherein said taxane is a paclitaxel analog.

148-177. (Canceled).